Sepracor withdraws Lunivia EU filing
This article was originally published in Scrip
Executive Summary
Sepracor has withdrawn the EU marketing application for its insomnia drug, Lunivia (eszopiclone) 2mg and 3mg tablets, as a result of the CHMP maintaining its recommendation that Lunivia should not be regarded as a new active substance.